Targeting the latent cytomegalovirus reservoir with an antiviral fusion toxin protein

Autor: Krishna, B.A., Spiess, K., Poole, E.L., Lau, B., Voigt, S., Kledal, T.N., Rosenkilde, M.M., Sinclair, J.H.
Přispěvatelé: Krishna, Benjamin Anthony Cates [0000-0003-0919-2961], Poole, Emma [0000-0003-3904-6121], Sinclair, John [0000-0002-2616-9571], Apollo - University of Cambridge Repository
Jazyk: angličtina
Rok vydání: 2017
Předmět:
Zdroj: Krishna, B A, Spiess, K, Poole, E L, Lau, B, Voigt, S, Kledal, T N, Rosenkilde, M M & Sinclair, J H 2017, ' Targeting the latent cytomegalovirus reservoir with an antiviral fusion toxin protein ', Nature Communications, vol. 8, 14321 . https://doi.org/10.1038/ncomms14321
Nature Communications
Nature Communications, Vol 8, Iss 1, Pp 1-9 (2017)
ISSN: 2041-1723
Popis: Reactivation of human cytomegalovirus (HCMV) in transplant recipients can cause life-threatening disease. Consequently, for transplant recipients, killing latently infected cells could have far-reaching clinical benefits. In vivo, myeloid cells and their progenitors are an important site of HCMV latency, and one viral gene expressed by latently infected myeloid cells is US28. This viral gene encodes a cell surface G protein-coupled receptor (GPCR) that binds chemokines, triggering its endocytosis. We show that the expression of US28 on the surface of latently infected cells allows monocytes and their progenitor CD34+ cells to be targeted and killed by F49A-FTP, a highly specific fusion toxin protein that binds this viral GPCR. As expected, this specific targeting of latently infected cells by F49A-FTP also robustly reduces virus reactivation in vitro. Consequently, such specific fusion toxin proteins could form the basis of a therapeutic strategy for eliminating latently infected cells before haematopoietic stem cell transplantation.
Reactivation of human cytomegalovirus in immunosuppressed transplant patients can cause severe complications. Here, Krishna et al. show that a fusion toxin protein that specifically binds the viral surface protein US28 can be used to kill latently infected monocytes and their progenitor cells in vitro.
Databáze: OpenAIRE